Compare MRK & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRK | SRPT |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2B | 2.3B |
| IPO Year | N/A | 1997 |
| Metric | MRK | SRPT |
|---|---|---|
| Price | $106.58 | $21.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 29 |
| Target Price | ★ $111.93 | $26.23 |
| AVG Volume (30 Days) | ★ 14.6M | 3.0M |
| Earning Date | 02-03-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 58.08 | N/A |
| EPS | ★ 7.56 | N/A |
| Revenue | ★ $64,235,000,000.00 | $2,413,715,000.00 |
| Revenue This Year | $1.98 | $13.72 |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $14.11 | ★ N/A |
| Revenue Growth | 1.68 | ★ 47.15 |
| 52 Week Low | $73.31 | $10.42 |
| 52 Week High | $107.59 | $129.84 |
| Indicator | MRK | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 68.51 | 52.20 |
| Support Level | $96.79 | $21.36 |
| Resistance Level | $107.59 | $22.52 |
| Average True Range (ATR) | 2.11 | 1.00 |
| MACD | 0.31 | -0.03 |
| Stochastic Oscillator | 88.04 | 48.62 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.